NeoPACT Phase 2 Clinical Trial
JAMA Oncology
NeoPACT evaluated an anthracycline-free combination of pembrolizumab, carboplatin and docetaxel before surgery for patients with stage I to III triple-negative breast cancer. The phase 2 study reported clinical outcomes and examined how immune biomarkers related to treatment response.
Read publication summary